IBO IMPACT BIOMEDICAL INC.
Pharmaceutical Preparations · NYSE · SEC CIK 1834105 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY103.7%
TTM EPS YoY184.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-12,655.3%
Net margin4,247.4%
FCF margin—
EBITDA margin-9,657.9%
Returns
ROE—
ROA9.3%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets18.6%
Debt / equity0.00x
Current ratio0.04x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.07x
Accruals ratio8.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $21,000 | $3,000 | $7,000 | $7,000 | $18,000 | $7,000 | — | — |
| Cost of revenue | $6,000 | $1,000 | — | $422,000 | $1,000 | $1,000 | — | — |
| Gross profit | $15,000 | $2,000 | — | -$415,000 | $17,000 | $6,000 | — | — |
| R&D expense | $35,000 | $76,000 | $46,000 | $110,000 | $52,000 | $75,000 | $103,000 | -$108,000 |
| SG&A expense | $156,000 | $167,000 | $1.62M | $118,000 | $261,000 | $246,000 | $248,000 | $294,000 |
| Operating income | -$648,000 | -$702,000 | -$2.29M | -$1.17M | -$948,000 | -$1.15M | -$1.01M | -$26.23M |
| Interest expense | — | — | — | $0 | $262,000 | $260,000 | $271,000 | $270,000 |
| Pretax income | -$644,000 | -$700,000 | -$2.28M | $2.65M | -$1.48M | -$14.35M | -$1.28M | -$27.10M |
| Net income | -$645,000 | -$699,000 | -$2.29M | $5.25M | -$1.47M | -$14.35M | -$1.27M | -$27.07M |
| EBITDA | -$364,000 | -$418,000 | -$2.00M | -$884,000 | -$660,000 | -$865,000 | -$727,000 | -$25.95M |
| EPS (basic) | -0.08 | -0.01 | -0.02 | — | -1.52 | -1.18 | -0.11 | — |
| EPS (diluted) | -0.08 | -0.01 | -0.02 | — | -1.52 | -1.18 | -0.11 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $21,000 | $10,000 | $20,000 | $3,000 | $12,000 | $624,000 | $1.32M | $2.00M |
| Receivables | — | — | — | $5,000 | $15,000 | $200,000 | $4,000 | $201,000 |
| Inventory | $56,000 | $62,000 | $63,000 | $63,000 | $485,000 | $486,000 | $489,000 | — |
| Current assets | $102,000 | $320,000 | $377,000 | $411,000 | $917,000 | $1.48M | $2.18M | $2.45M |
| PP&E, net | — | — | — | — | $13,000 | $14,000 | $16,000 | $17,000 |
| Goodwill | — | — | — | — | — | — | — | $25.09M |
| Intangibles | $16.14M | $16.43M | $16.71M | $16.99M | $17.28M | $17.57M | $17.85M | $17.81M |
| Total assets | $16.43M | $16.75M | $17.09M | $17.41M | $18.21M | $19.06M | $20.05M | $20.29M |
| Current liabilities | $2.37M | $2.04M | $1.69M | $1.16M | $23.79M | $23.17M | $9.97M | $9.79M |
| Total liabilities | $3.06M | $2.73M | $2.38M | $1.85M | $27.06M | $26.44M | $13.24M | $13.05M |
| Shareholders' equity | $10.12M | $10.77M | $11.46M | $12.31M | -$11.81M | -$10.34M | $3.84M | $4.26M |
| Shares outstanding | 8.54M | 107.82M | 107.82M | 8.29M | 12.19M | 12.19M | 12.09M | 11.50M |
| Cash flow statement | ||||||||
| Operating cash flow | $11,000 | $470,000 | -$464,000 | $99,000 | -$613,000 | -$694,000 | -$682,000 | -$986,000 |
| Investing cash flow | $0 | $2,000 | -$1,000 | $1,000 | $1,000 | $0 | $1,000 | $0 |
| Financing cash flow | — | — | $482,000 | — | — | — | — | $317,000 |
| Depreciation & amortization | $284,000 | $284,000 | $285,000 | $286,000 | $288,000 | $288,000 | $283,000 | $279,000 |
| Stock-based compensation | $0 | $0 | $1.44M | $8,000 | $2,000 | $2,000 | $2,000 | $19,000 |
Free plan shows the latest 8 periods; Pro shows all 18 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.